TIDMAGL
Angle PLC
29 March 2022
For immediate release 29 March 2022
ANGLE plc ("the Company")
PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION
ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS
Existing chemotherapies, such as vinorelbine, may selectively
target and reduce the metastatic potential of CTCs
Detecting a reduction of microtentacles, that enable the spread
of cancer, on live CTCs indicates a positive response to
therapy
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that the University of Maryland
Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute,
Baltimore, Maryland, USA, has published results of work undertaken
in preclinical models of triple-negative breast cancer (TNBC),
showing that isolation of live circulating tumour cells (CTCs) from
a simple blood draw, using the Parsortix(R) system, can provide
rapid information on patient response to existing chemotherapy
treatments that can target metastasis more effectively than tumour
growth.
The research team has previously demonstrated that breast cancer
cells circulating in the blood form unique microtentacles that
enable the spread and formation of tumours at secondary sites.
Microtentacles are supported by microtubules, which are the target
for many FDA-approved chemotherapy drugs, such as vinorelbine used
in this study.
Using preclinical TNBC models, the researchers showed that
vinorelbine treatment increased the time taken for the cancer to
spread from 8 to 30 weeks. However, a 24-hour vinorelbine treatment
had little effect on the primary tumour development and survival,
indicating selective targeting of the metastatic potential of CTCs
through microtubule disruption. The results of this study indicate
that CTCs demonstrate specific features which can be leveraged to
reveal the anti-metastatic capabilities of vinorelbine and
potentially other existing FDA-approved therapies.
In the US, breast cancer is the most frequently diagnosed cancer
in women with 287,000 new cases expected in 2022, accounting for
31% of all new cancer cases. The American Cancer Society estimates
that TNBC accounts for about 10-15% of all breast cancers. TNBC
differs from other types of invasive breast cancer in that it grows
and spreads faster, has limited treatment choices, and a worse
prognosis. TNBC patients are recommended for chemotherapy
treatments, due to lack of targeted therapies, yet some
pre-clinical studies have shown that neoadjuvant chemotherapy can
increase the risk of metastasis. There is an urgent need to improve
treatment options for patients with early stage TNBC that can
reduce the metastatic risk.
Prof Stuart Martin, University of Maryland Marlene and Stewart
Greenebaum Comprehensive Cancer Center, commented:
"Cancer drugs that broadly disrupt microtubules have long proven
effective at reducing tumor growth and improving patient survival,
but also have significant toxicities that limit dosing. The focused
treatment reported here reduced microtentacles and metastasis at
well below the maximum-tolerated dose. If it is possible to use a
focused treatment to reduce CTC metastasis, the most likely
opportunity for therapies to reduce CTC metastasis would be
combination therapy at the time of primary tumor treatment, helping
to ensure that CTCs shed by that primary tumor treatment have
reduced metastatic potential".
ANGLE Founder and Chief Executive, Andrew Newland, added:
"We are pleased to report on the use of the Parsortix system for
the isolation of live CTCs in pre-clinical TNBC models, uncovering
the potential to provide rapid information on how a patient is
responding to a therapy. ANGLE's ability to provide actionable
insight could help patients with limited treatment options and
could help to identify already approved drugs that could target
highly metastatic and hard-to-treat cancers, such as TNBC."
The research has been published as a peer-reviewed publication
in the journal Breast Cancer Research and is available online at
https://angleplc.com/library/publications/ .
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Jen Clarke, Milo Bonser, Shiv Dave +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Max Jones, Thomas Bective +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen; as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and a 200 patient
clinical verification study has now completed enrolment.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) platform and is
based on a patented flow through array technology. It provides for
low cost, highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry approach (the HyCEAD method) allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. The HyCEAD system is extremely sensitive and is ideal for
measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test
to achieve best in class accuracy (AUC-ROC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
58 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of Parsortix in cancer drug trials and, once the
laboratories are accredited and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASDPASSAEFA
(END) Dow Jones Newswires
March 29, 2022 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
